:: Volume 32, Issue 3 (Fall 2022) ::
MEDICAL SCIENCES 2022, 32(3): 239-245 Back to browse issues page
A review of the mucormycosis prevalence during the pandemic of the coronavirus (Covid-19) worldwide
Javad Cheraghi1 , Aref Nooraee 2, Marzie Havasii3 , Salman Soltani4 , Kaveh Khazaeel5
1- Department of Laboratory Sciences, Ilam School of Paramedical Sciences, Ilam, Iran
2- PhD in Comparative Anatomy and Embryology, Faculty of Paraveterinary Medicine, University of Ilam, Iran , aref.noraie2012@gmail.com
3- MSc in Clinical Biochemistry, Ilam University of Medical Sciences, Ilam, Iran
4- PhD in Comparative Histology, Research Center of Ilam University, Ilam, Iran
5- Assistant Professor of Anatomical Sciences, Department of Basic Sciences, Faculty of Veterinary Medicine, Shahid Chamran University of Ahvaz, Iran
Abstract:   (1629 Views)
Background: The COVID-19 was first reported in 2019 in Wuhan, China, and spread rapidly in China and other countries. The virus was followed by a wide range of bacterial and opportunistic fungal diseases, including fungal infections such as mucormycosis.
Materials and methods: In this narrative review study, scientific databases, such as PubMed, Google Scholar and Springer were searched with the keywords, including Mucormycosis and COVID-19 in the time period between 2020 February and July 2021. 27 articles were retrieved, in which 18 articles were used in the study and 9 were excluded.
Results: So far, many people with the coronavirus have been infected by black fungus in the world. Most affected people had the history of diabetes mellitus and also receiving high dose corticosteroids.
Conclusion: Recently, with the outbreak of a new wave of the deadly Covid 19 virus in India, there have been many cases of mucormycosis. Mucocycosis is fatal in about 30% of cases.
 
Keywords: COVID-19, Mucormycosis, Prevalence
Full-Text [PDF 400 kb]   (902 Downloads)    
Semi-pilot: Systematic Review | Subject: Parasitology
Received: 2022/03/4 | Accepted: 2022/04/19 | Published: 2022/09/1
References
1. Cucinotta D, Vanelli M. WHO Declares COVID-19 a Pandemic. Acta Biomed 2020; 91: 157-60.
2. Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia N Engl J Med 2020;382:1199-207.
3. Ren LL, Wang YM, Wu ZQ, Xiang ZC, Guo L, Xu T, et al. Identification of a novel coronavirus causing severe pneumonia in human: a descriptive study. Chin Med J (Engl) 2020;133:1015-24. [DOI:10.1097/CM9.0000000000000722]
4. Lu CW, Liu XF, Jia ZF. 2019-nCoV transmission through the ocular surface must not be ignored. Lancet 2020;395:e39. [DOI:10.1016/S0140-6736(20)30313-5]
5. Kubin CJ, McConville TH, Dietz D, Zucker J, May M, Nelson B, et al. Characterization of Bacterial and Fungal Infections in Hospitalized Patients With Coronavirus Disease 2019 and Factors Associated With Health Care-Associated Infections. Open Forum Infect Dis 2021;8:ofab201. [DOI:10.1093/ofid/ofab201]
6. Song G, Liang G, Liu W. Fungal Co-infections Associated with Global COVID-19 Pandemic: A Clinical and Diagnostic Perspective from China. Mycopathologia 2020 ;185:599-606. [DOI:10.1007/s11046-020-00462-9]
7. Hibbett DS, Binder M, Bischoff JF, Blackwell M, Cannon PF, Eriksson OE, et al. A higher-level phylogenetic classification of the Fungi. Mycol Res 2007;111:509-47. [DOI:10.1016/j.mycres.2007.03.004]
8. Spellberg B, Edwards J Jr, Ibrahim A. Novel perspectives on mucormycosis: pathophysiology, presentation, and management. Clin Microbiol Rev 2005;18:556-69. [DOI:10.1128/CMR.18.3.556-569.2005]
9. Prakash H, Chakrabarti A. Epidemiology of Mucormycosis in India. Microorganisms 2021;9:523. [DOI:10.3390/microorganisms9030523]
10. Tedder M, Spratt JA, Anstadt MP, Hegde SS, Tedder SD, Lowe JE. Pulmonary mucormycosis: results of medical and surgical therapy. Ann Thorac Surg 1994;57:1044-50. [DOI:10.1016/0003-4975(94)90243-7]
11. Torres-Narbona M, Guinea J, Martínez-Alarcón J, Muñoz P, Gadea I, Bouza E. MYCOMED Zygomycosis Study Group. Impact of zygomycosis on microbiology workload: a survey study in Spain. J Clin Microbiol 2007;45:2051-3. [DOI:10.1128/JCM.02473-06]
12. Singh A K, Singh R, Joshi SR, Misra A. Mucormycosis in COVID-19: a systematic review of cases reported worldwide and in India. Diabetes Metab Syndr 2021;15:102146. [DOI:10.1016/j.dsx.2021.05.019]
13. Veisi A, Bagheri A, Eshaghi M, Rikhtehgar MH, Rezaei Kanavi M, Farjad R. Rhino-orbital mucormycosis during steroid therapy in COVID-19 patients: A case report. Eur J Ophthalmol 2022;32:NP11-16. [DOI:10.1177/11206721211009450]
14. Saldanha M, Reddy R, Vincent MJ. Title of the Article: Paranasal Mucormycosis in COVID-19 Patient. Indian J Otolaryngol Head Neck Surg 2021:1-4. [DOI:10.1007/s12070-021-02574-0]
15. Werthman-Ehrenreich A. Mucormycosis with orbital compartment syndrome in a patient with COVID-19. Am J Emerg Med 2021;42:264.e5-264.e8. [DOI:10.1016/j.ajem.2020.09.032]
16. Sugar AM. Mucormycosis. Clin Infect Dis 1992;14:S126-29. [DOI:10.1093/clinids/14.Supplement_1.S126]
17. Prakash H, Ghosh AK, Rudramurthy SM, Singh P, Xess I, Savio J, et al. A prospective multicenter study on mucormycosis in India: Epidemiology, diagnosis, and treatment. Med Mycol 2019;57:395-402. [DOI:10.1093/mmy/myy060]
18. Patel A, Kaur H, Xess I, Michael JS, Savio J, Rudramurthy S, et al. A multicentre observational study on the epidemiology, risk factors, management and outcomes of mucormycosis in India. Clin Microbiol Infect 2020;26:944.e9-944.e15. [DOI:10.1016/j.cmi.2019.11.021]



XML   Persian Abstract   Print



Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Volume 32, Issue 3 (Fall 2022) Back to browse issues page